Chinese Migrant Population Health Cohort
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 26,000
- 试验地点
- 1
- 主要终点
- Number of Participants Experiencing First Major Cardiovascular Event
研究概览
简要总结
The Chinese Migrant Population Health Cohort is a prospective, multi-center study jointly initiated by Professor Yong Ji, President of Harbin Medical University, and Academician Guoqiang Chen, President of Hainan Medical University, in collaboration with regional partners. It targets older adults (≥60 years) who engage in seasonal migration between cold (Heilongjiang) and tropical (Hainan) regions. The primary objective is to investigate cardiovascular and metabolic disease risks, underlying biological and environmental mechanisms, and effective preventive strategies in this unique population.
Participants are recruited from both origin and destination sites and undergo standardized baseline assessments, including questionnaires, physical examinations, medical imaging, biospecimen collection (blood, stool, hair, nails), and environmental exposure monitoring. Longitudinal follow-up includes periodic reassessments, remote monitoring, and data linkage with hospital information systems to capture health outcomes.
The study aims to:
Define migration-related health risk profiles and disease phenotypes.
Elucidate biological and environmental mechanisms influencing disease onset and progression.
Develop AI-driven risk prediction models and evaluate targeted interventions through nested randomized controlled trials.
Translate findings into clinical guidelines and scalable cross-regional health management models.
This is the first cohort in China to systematically investigate the health impacts of seasonal migration in older adults. By integrating epidemiology, multi-omics, environmental data, and health policy translation, the study seeks to improve continuity of care, strengthen climate adaptation, and promote healthy ageing.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 60 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Permanent residents of Harbin or Hainan who will continue to reside in Harbin or Hainan for the next 5 years.
- •Baseline age ≥60 years, with basic communication and comprehension abilities.
- •No confirmed diagnosis of end-stage major organic diseases (e.g., advanced heart failure, advanced liver failure, advanced kidney failure, malignant tumors).
- •Able to perform activities of daily living independently and capable of completing questionnaires and physical examinations.
- •Willing to participate in the study, provide written informed consent, accept long-term follow-up, and provide biological specimens.
排除标准
- •Occurrence of life-threatening acute events (e.g., myocardial infarction, acute heart failure, stroke) within the past 30 days.
- •Currently receiving chronic treatment with antiviral drugs (e.g., for HIV) or antipsychotic medications.
- •Presence of moderate to severe cognitive impairment preventing survey completion or follow-up cooperation.
- •Current acute infectious diseases such as influenza or fever.
- •Simultaneous participation in other interventional clinical studies.
- •Refusal to sign informed consent or unwillingness to provide biological specimens.
- •Any other condition deemed unsuitable for study participation by the investigators based on overall assessment.
结局指标
主要结局
Number of Participants Experiencing First Major Cardiovascular Event
时间窗: Up to 5 years from baseline
First occurrence of myocardial infarction, stroke (ischemic or hemorrhagic), or cardiovascular death, confirmed through hospital records, death registries, and adjudication committee review.
次要结局
- Number of Participants with New-Onset Metabolic Disorders(Up to 5 years from baseline)
- Number of Deaths from Any Cause(Up to 5 years from baseline)
- Changes in Cardiometabolic Risk Factors(Baseline, 2 years, 4 years)
- Change in EQ-5D Quality of Life Score from Baseline(Baseline, 2 years, 4 years)
- Change in Cognitive Function Score (MoCA) from Baseline(Baseline, 2 years, 4 years)
研究者
Jinwei Tian
Doctor
Harbin Medical University